Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

20062,926 citationsJournal Article

Authors

Steven E. Kahn · VA Puget Sound Health Care System

Steven M. Haffner · The University of Texas Health Science Center at San Antonio

Mark Heise · GlaxoSmithKline (United States)

William H. Herman · University of Michigan–Ann Arbor

Rury R. Holman · Oxford Centre for Diabetes, Endocrinology and Metabolism

Nigel C. Jones · Harlow College

Barbara G. Kravitz

Abstract

The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).

Topics & Keywords

Metabolism, Diabetes, and Cancer Diabetes Treatment and Management Peroxisome Proliferator-Activated Receptors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 23, pp. 2427-2443

DOI: 10.1056/nejmoa066224

Field-Weighted Citation Impact: 96.72